Scientific Publications
29Mar, 2017
Tramiprosate Efficacy in APOE4 Homozygous Subjects with AD: Larger Effects in Mild Patient Subgroups
Abstract OBJECTIVES: ALZ-801 is an oral pro-drug of tramiprosate being developed as a [...]
9Dec, 2016
Phase 1 Program of ALZ-801, a Novel Prodrug of Tramiprosate with Improved Tolerability, Supports Bridging to Upcoming Phase 3 Program
Presented at the 9th annual Clinical Trials on Alzheimer’s Disease (CTAD) conference, held [...]
28Oct, 2016
Clinical Benefits of Tramiprosate in Alzheimer’s Disease Are Associated with Higher Number of APOE4 Alleles: The “APOE4 Gene-Dose Effect”
S. Abushakra, A. Porsteinsson, B.Vellas, J. Cummings, S. Gauthier, J.A. Hey, A. Power, [...]
24Jul, 2016
Clinically Meaningful Cognitive and Functional Improvements with Tramiprosate In Alzheimer’s Disease (AD) Patients with APOE4/4 Genotype: Subgroup Analyses from Two Phase 3 Studies
Presented at the Alzheimer's Association International Conference (AAIC) 2016 in Toronto, Canada Abstract Background: [...]
24Jul, 2016
Phase 1 Development Of ALZ-801, a Novel Beta Amyloid Anti-aggregation Prodrug of Tramiprosate With Improved Drug Properties, Supporting Bridging to the Phase 3 Program
Presented at the Alzheimer's Association International Conference (AAIC) 2016 in Toronto, Canada Abstract Background: [...]
11Mar, 2016
Efficacy of tramiprosate in APOE4 heterozygous patients with mild to moderate AD: combined sub-group analyses from two Phase 3 trials
Presented at the 14th Annual International Athens/Springfield Symposium on Advances in Alzheimer Therapies [...]